Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22040115 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL22040119 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL22040821 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL24350293 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL22040116 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL24350710 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL22039498 | 1.00 | EP300 (0.72) | EP300CREBBP | |
| SCHEMBL24349842 | 0.98 | EP300 (0.71) | EP300CREBBP | |
| SCHEMBL24350098 | 0.98 | EP300 (0.71) | EP300CREBBP | |
| SCHEMBL23878269 | 0.98 | EP300 (0.71) | EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| WO-2020108500-A1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | 成都海创药业有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | EP300 1/4885CREBBP 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.